Rheumatology

Investigators conducted a review of 21 studies on the effects of a gum disease treatment on various rheumatoid arthritis (RA) disease activity measures.

Juvenile idiopathic arthritis (JIA) disease flare was significantly longer in children with enthesitis-related arthritis and juvenile psoriatic arthritis treated with secukinumab compared with placebo.

While past research suggests patients with rheumatoid arthritis (RA) are at increased risk for dementia, a Mayo Clinic study claims this is not the case.

The new report reverses previous research suggesting that White men who consumed large amounts of gamey meat and rich foods were most at risk.

The summary includes expanded indications for certain vaccines, approaches for live-attenuated vaccines, and medication management around the time of vaccination for patients with rheumatic and musculoskeletal diseases (RMDs).

According to the review, the most important novel developments were related to the repositioning of old drugs in the context of treat-to-target (T2T) therapy and new long-term safety information on Janus kinase (JAK) inhibitors.

Patients with gout who experienced a heart attack or stroke were twice as likely to have experienced a gout flare within the past 60 days compared with patients with gout who did not experience either event.

Interviews conducted with patients with rheumatoid arthritis (RA) revealed 6 important aspects of daily life that are rarely measured in RA research.

While a 1-year course of methotrexate improved physical function, pain, morning joint stiffness, and joint inflammation, it did not prevent the development of clinical arthritis.

A systemic review found that patients with rheumatic diseases experienced comparable outcomes and satisfaction from telemedicine compared with in-person treatment.

A review found rheumatic conditions cause 22.2% of global cases of fever and inflammation of unknown origin.

None of the adolescent and young adult (AYA) participants in a study reported experiencing the Six Core Elements of Healthcare Transition during their rheumatology health care transition.

Participants in a digital acute musculoskeletal (MSK) program experienced better pain and function outcomes vs nonparticipants, demonstrating benefits for acute and subacute MSK conditions.

Pegloticase (Krystexxa) injection coadministered with methotrexate received FDA approval for the treatment of gout.

Researchers found that risk of adverse events and mortality did not increase following certain rheumatoid arthritis (RA) treatments.

Outcomes for patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) may depend on gender, time to diagnosis, and body mass index (BMI), according to subanalyses of the AQUILA study of patients taking secukinumab.

Abstracts presented at EULAR 2022 focused on racial differences in gout prevalence and treatment, highlighting racial disparities in recent decades.

Based on limited existing evidence, a systematic review found no single dietary factor had a meaningful impact on rheumatic and musculoskeletal disease (RMD) outcomes.

Adults aged 50 and older who walked for exercise were less likely to develop new frequent knee pain and medial joint space narrowing.

Prior miscarriage and antinuclear antibody positivity are independent risk factors associated with adverse pregnancy outcomes among women with rheumatoid arthritis (RA).

The developers of these models said the next step is to determine how to incorporate these patient perspectives into clinical rheumatology practice.

Abstracts presented at EULAR 2022 focused on sex-related differences in inflammatory arthritis (IA) management, including adherence to electronically reporting outcomes and disparities in health care utilization.

Undifferentiated connective tissue disease (UCTD) is challenging to define but is a distinct clinical entity from connective tissue diseases (CTD).

Research supports that aquatic exercise is effective at reducing pain and disease activity and improving physical function, although it is unclear whether it is more effective than any other form of therapy for inflammatory arthritis (IA).

A letter from the American College of Rheumatology (ACR) called for drug pricing reforms, deeming them necessary to ensure the health of patients and sustainability of health care systems.

Over 48 weeks, secukinumab was shown to be effective and safe in a small study of 18 children with generalized pustular psoriasis in China.

While current data on medical cannabinoids in rheumatology is limited, findings suggest that adverse events (AEs) and drug interactions outweigh the benefits.

Researchers found that the extreme gradient boosting (XGBoost) predictor could more accurately predict rheumatoid arthritis (RA) relapse than logistic regression and random forest.

Male sex, older age, lower socioeconomic status, higher comorbidity score, and having an older or male rheumatologist were associated with the reduced likelihood of continuing with rheumatoid arthritis (RA) treatment.

According to the authors, sex-based differences may be a cause of higher rheumatoid arthritis (RA) disease activity.